ArticleHematology. American Society of Hematology. Education Program2025
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.
Article in Hematology. American Society of Hematology. Education Program, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of T-cell redirecting strategies, including chimeric antigen receptor T cells and bispecific antibodies, has significantly improved the prognosis of patients with relapsed/refractory large B-cell lymphoma. Current, ongoing clinical trials are exploring their role in earlier treatment lines, rapidly reshaping the treatment landscape of this disease entity. The field has shifted from the concept of transplant-eligible to chimeric antigen receptor T-cell eligible, albeit current trials still consider the former to define the target patient population. Here, we discuss 2 clinical cases to deliberately illustrate this dynamic era of T-cell redirecting strategies, highlighting the main learning points but also presenting the opportunities and open questions to be addressed in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.